PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
26013824-8	2015	Similarly to the mesotrypsin phenotype, CTRC variant p.G214R was inhibited poorly by eglin C, ecotin, or a CTRC-specific variant of SGPI-2, and it readily cleaved the reactive-site peptide bonds in eglin C and ecotin.	ecotin	94-100	chymotrypsin C	Homo sapiens	40-44
26013824-8	2015	Similarly to the mesotrypsin phenotype, CTRC variant p.G214R was inhibited poorly by eglin C, ecotin, or a CTRC-specific variant of SGPI-2, and it readily cleaved the reactive-site peptide bonds in eglin C and ecotin.	ecotin	210-216	chymotrypsin C	Homo sapiens	40-44
16763560-5	2006	In vivo administration of a plasma kallikrein (pKal)-selective form of the serine protease inhibitor ecotin exacerbates the healing impairment of uPA;tPA double-deficient wounds to a degree indistinguishable from that observed in Plg-deficient mice, and completely blocks the activity of pKal, but not uPA and tPA in wound extracts.	ecotin	101-107	plasminogen activator, urokinase	Mus musculus	146-149
20180651-9	2010	We used ecotin-Pkal to specifically inhibit contact activation of human plasma at the level mediated by plasma kallikrein.	ecotin	8-14	kallikrein B1	Homo sapiens	15-19
20180651-9	2010	We used ecotin-Pkal to specifically inhibit contact activation of human plasma at the level mediated by plasma kallikrein.	ecotin	8-14	kallikrein B1	Homo sapiens	104-121
19297327-5	2009	We used a variant of ecotin (ecotin-PKal), a macromolecular inhibitor of serine proteases engineered to be highly specific for active PKal, to demonstrate that inhibition of PKal with ecotin-PKal delays alveolar apoptosis, adipocyte replenishment, and stromal remodeling in the involuting mammary gland, producing a phenotype resembling that resulting from plasminogen deficiency.	ecotin	21-27	kallikrein B1	Homo sapiens	36-40
19297327-5	2009	We used a variant of ecotin (ecotin-PKal), a macromolecular inhibitor of serine proteases engineered to be highly specific for active PKal, to demonstrate that inhibition of PKal with ecotin-PKal delays alveolar apoptosis, adipocyte replenishment, and stromal remodeling in the involuting mammary gland, producing a phenotype resembling that resulting from plasminogen deficiency.	ecotin	21-27	kallikrein B1	Homo sapiens	134-138
19297327-5	2009	We used a variant of ecotin (ecotin-PKal), a macromolecular inhibitor of serine proteases engineered to be highly specific for active PKal, to demonstrate that inhibition of PKal with ecotin-PKal delays alveolar apoptosis, adipocyte replenishment, and stromal remodeling in the involuting mammary gland, producing a phenotype resembling that resulting from plasminogen deficiency.	ecotin	21-27	kallikrein B1	Homo sapiens	134-138
19728173-8	2010	Haptoglobin does not prevent ecotin inhibition of u-PA, but it may act as a carrier within blood when ecotin is used in vivo.	ecotin	102-108	haptoglobin	Homo sapiens	0-11
16763560-5	2006	In vivo administration of a plasma kallikrein (pKal)-selective form of the serine protease inhibitor ecotin exacerbates the healing impairment of uPA;tPA double-deficient wounds to a degree indistinguishable from that observed in Plg-deficient mice, and completely blocks the activity of pKal, but not uPA and tPA in wound extracts.	ecotin	101-107	promotion susceptibility QTL 1	Mus musculus	150-153
16763560-5	2006	In vivo administration of a plasma kallikrein (pKal)-selective form of the serine protease inhibitor ecotin exacerbates the healing impairment of uPA;tPA double-deficient wounds to a degree indistinguishable from that observed in Plg-deficient mice, and completely blocks the activity of pKal, but not uPA and tPA in wound extracts.	ecotin	101-107	plasminogen	Mus musculus	230-233
16763560-5	2006	In vivo administration of a plasma kallikrein (pKal)-selective form of the serine protease inhibitor ecotin exacerbates the healing impairment of uPA;tPA double-deficient wounds to a degree indistinguishable from that observed in Plg-deficient mice, and completely blocks the activity of pKal, but not uPA and tPA in wound extracts.	ecotin	101-107	plasminogen activator, urokinase	Mus musculus	302-305
16763560-5	2006	In vivo administration of a plasma kallikrein (pKal)-selective form of the serine protease inhibitor ecotin exacerbates the healing impairment of uPA;tPA double-deficient wounds to a degree indistinguishable from that observed in Plg-deficient mice, and completely blocks the activity of pKal, but not uPA and tPA in wound extracts.	ecotin	101-107	promotion susceptibility QTL 1	Mus musculus	310-313
16843700-9	2006	Finally, solid phase competition assays demonstrated that heparin and prothrombin fragment 2 prevents thrombin interaction with ecotin.	ecotin	128-134	coagulation factor II, thrombin	Homo sapiens	73-81
16843700-0	2006	Ecotin modulates thrombin activity through exosite-2 interactions.	ecotin	0-6	coagulation factor II, thrombin	Homo sapiens	17-25
31860690-4	2019	We show that ecotin inhibits MASP-3, which is the sole factor D activator in resting human blood.	ecotin	13-19	MBL associated serine protease 1	Homo sapiens	29-35
16843700-3	2006	In this work we showed that ecotin binds to human alpha-thrombin via its secondary binding site, and modulates thrombin catalytic activity.	ecotin	28-34	coagulation factor II, thrombin	Homo sapiens	56-64
16843700-3	2006	In this work we showed that ecotin binds to human alpha-thrombin via its secondary binding site, and modulates thrombin catalytic activity.	ecotin	28-34	coagulation factor II, thrombin	Homo sapiens	111-119
16843700-7	2006	Complex formation with ecotin caused a three-fold increase in the rate of thrombin inhibition by BPTI, suggesting a displacement of the enzyme"s 60-loop.	ecotin	23-29	coagulation factor II, thrombin	Homo sapiens	74-82
16843700-8	2006	In addition, ecotin modulated the enzyme"s catalytic site, as demonstrated by changes in the fluorescence emission of fluorescein-FPRCK-alpha-thrombin (EC50=3.5 microM).	ecotin	13-19	coagulation factor II, thrombin	Homo sapiens	142-150
14705961-9	2004	Ecotin affects primarily the ability of E. coli to recover and grow following treatment with neutrophil elastase, rather than the actual rate of killing.	ecotin	0-6	elastase, neutrophil expressed	Homo sapiens	93-112
11959867-7	2002	One of these combinations (D70R/M84R/RRQL) is the tightest (K(i) = 50 pm) ecotin variant inhibitor of uPA.	ecotin	74-80	plasminogen activator, urokinase	Homo sapiens	102-105
11231576-4	2001	PKal, which is inhibited by ecotin, is required for adipose conversion, Plg activation and 3T3-L1 differentiation.	ecotin	28-34	kallikrein B, plasma 1	Mus musculus	0-4
11231576-4	2001	PKal, which is inhibited by ecotin, is required for adipose conversion, Plg activation and 3T3-L1 differentiation.	ecotin	28-34	plasminogen	Mus musculus	72-75
7781771-6	1995	The potent anticoagulant effect by ecotin is explained by the coincident inhibition of FXIIa, kallikrein, and FXa and suggests that it may be useful in the study of inflammatory or thrombotic disorders such as sepsis or cardiopulmonary bypass.	ecotin	35-41	coagulation factor X	Homo sapiens	110-113
32657577-0	2020	Structural basis for the inhibition mechanism of ecotin against neutrophil elastase by targeting the active site and secondary binding site.	ecotin	49-55	elastase, neutrophil expressed	Homo sapiens	64-83
12834348-5	2003	Gln 192 from FXa forms a hydrogen bond with the P2 carbonyl group of ecotin.	ecotin	69-75	coagulation factor X	Homo sapiens	13-16
9642073-5	1998	The interactions of the secondary binding site of ecotin with bovine trypsin, rat trypsin and human urokinase-type plasminogen activator (uPA) were investigated with alanine substitutions in ecotin at Trp67, Gly68, Tyr69, Asp70, Arg108, Asn110, Lys112 and Leu113, which formed contacts between the inhibitor and protease.	ecotin	50-56	plasminogen activator, urokinase	Homo sapiens	100-136
9642073-5	1998	The interactions of the secondary binding site of ecotin with bovine trypsin, rat trypsin and human urokinase-type plasminogen activator (uPA) were investigated with alanine substitutions in ecotin at Trp67, Gly68, Tyr69, Asp70, Arg108, Asn110, Lys112 and Leu113, which formed contacts between the inhibitor and protease.	ecotin	50-56	plasminogen activator, urokinase	Homo sapiens	138-141
9642077-2	1998	An approach using the three-dimensional structure of the ecotin-trypsin complex to guide combinatiorial design efforts was taken to create potent bidentate ecotin inhibitors for trypsin and human urokinase-type plasminogen activator (uPA).	ecotin	57-63	plasminogen activator, urokinase	Homo sapiens	196-232
9642077-2	1998	An approach using the three-dimensional structure of the ecotin-trypsin complex to guide combinatiorial design efforts was taken to create potent bidentate ecotin inhibitors for trypsin and human urokinase-type plasminogen activator (uPA).	ecotin	57-63	plasminogen activator, urokinase	Homo sapiens	234-237
9642077-9	1998	A second generation library, ecotin M84R+60X4 including an additional methionine to arginine substitution at position 84 in the primary binding site of ecotin, was generated for panning against uPA and rat trypsin.	ecotin	29-35	plasminogen activator, urokinase	Rattus norvegicus	194-197
9642077-12	1998	Ecotin M84R+D70R bound to uPA at 50 pM, a 56,000-fold increase in binding compared to ecotin WT.	ecotin	0-6	plasminogen activator, urokinase	Rattus norvegicus	26-29
9154920-1	1997	The crystal structure of fiddler crab collagenase complexed with the dimeric serine protease inhibitor ecotin at 2.5 A resolution reveals an extended cleft providing binding sites for at least 11 contiguous substrate residues.	ecotin	103-109	coagulation factor II, thrombin	Homo sapiens	77-92
7744876-0	1995	Isolation of a high affinity inhibitor of urokinase-type plasminogen activator by phage display of ecotin.	ecotin	99-105	plasminogen activator, urokinase	Homo sapiens	42-78
7744876-2	1995	However, although the catalytic domain of human urokinase-type plasminogen activator (uPA) has 40% identity to bovine trypsin and the substrate specificities of these two proteases are virtually identical, ecotin inhibits uPA almost 10,000-fold less efficiently than trypsin.	ecotin	206-212	plasminogen activator, urokinase	Homo sapiens	48-84
7744876-2	1995	However, although the catalytic domain of human urokinase-type plasminogen activator (uPA) has 40% identity to bovine trypsin and the substrate specificities of these two proteases are virtually identical, ecotin inhibits uPA almost 10,000-fold less efficiently than trypsin.	ecotin	206-212	plasminogen activator, urokinase	Homo sapiens	86-89
7744876-2	1995	However, although the catalytic domain of human urokinase-type plasminogen activator (uPA) has 40% identity to bovine trypsin and the substrate specificities of these two proteases are virtually identical, ecotin inhibits uPA almost 10,000-fold less efficiently than trypsin.	ecotin	206-212	plasminogen activator, urokinase	Bos taurus	222-225
8142399-0	1994	Ecotin is a potent anticoagulant and reversible tight-binding inhibitor of factor Xa.	ecotin	0-6	coagulation factor X	Homo sapiens	75-84
8142399-3	1994	The binding of ecotin to FXa was stoichiometric with an equilibrium dissociation constant Ki of 54 pM.	ecotin	15-21	coagulation factor X	Homo sapiens	25-28
8142399-12	1994	FXa cleaved ecotin slowly at pH 4.0 between M84 and M85.	ecotin	12-18	coagulation factor X	Homo sapiens	0-3
35014748-5	2022	Unexpectedly, compared with full-length ecotin, we find that our short linear peptides and circular amide-backbone-linked peptides of ecotin are incapable of efficient hNE inhibition.	ecotin	134-140	elastase, neutrophil expressed	Homo sapiens	168-171